胎盘生长因子、可溶性fms样酪氨酸激酶-1及糖基化纤连蛋白在子痫前期预测中的应用价值

杨岚, 肖建平, 石皓, 苏靖娜, 赵頔, 赵丽, 唐叶

PDF(685 KB)
PDF(685 KB)
重庆医科大学学报 ›› 2024, Vol. 49 ›› Issue (01) : 50-54. DOI: 10.13406/j.cnki.cyxb.003412
临床研究 DOI:10.13406/j.cnki.cyxb.003412

胎盘生长因子、可溶性fms样酪氨酸激酶-1及糖基化纤连蛋白在子痫前期预测中的应用价值

作者信息 +

Application value of placental growth factor,soluble fms-like tyrosine kinase-1,and glycosylated fibronectin in the prediction of preeclampsia

Author information +
History +

摘要

目的 探讨胎盘生长因子(placental growth factor,PLGF)、可溶性fms样酪氨酸激酶-1(soluble fms-like tyrosine kinase-1,SFLT-1)和糖基化纤连蛋白(glycosylated fibronectin,GLYFN)检测对子痫前期的预测价值。 方法 选择在无锡市妇幼保健院就诊的188例孕妇,分154例正常孕妇(对照组)和34例子痫前期患者(子痫组),应用免疫荧光法分别检测其在孕16~18周血清中PLGF、SFLT-1和GLYFN的浓度,比较子痫前期组和对照组各标志物的水平,并使用受试者操作特征曲线(receiver operating characteristic,ROC)对3种标志物的预测价值进行效能评估。 结果 在妊娠中期,子痫前期组血清PLGF浓度低于对照组,SFLT-1及GLYFN浓度均高于对照组,3种标志物的差异均有统计学意义(3指标P=0.000)。95%置信区间的ROC曲线下面积(areas under the ROC curve,AUC)为,PLGF为0.941(0.907~0.974),SFLT-1为0.881(0.800~0.962),GLYFN为0.951(0.918~0.985),联合指标SFLT-1和GLYFN、3项指标联合检测在ROC曲线下面积(areas under the ROC curve,AUC)分别为0.968、0.986。 结论 PLGF、SFLT-1、GLYFN 3种标志物水平在对照组和子痫前期组均存在明显差异,对子痫前期的发病具有一定的预测价值,SFLT-1联合PLGF、SFLT-1联合GLYFN、3项指标联合检测对子痫前期的预测价值高于任一单项指标。

Abstract

Objective To explore the value of placental growth factor(PLGF),soluble fms-like tyrosine kinase-1(SFLT-1),and glycosylated fibronectin(GLYFN) in predicting preeclampsia. Methods A total of 188 pregnant women who visited Wuxi Maternal and Child Health Hospital were enrolled in the study and divided into control group(154 normal pregnant women) and preeclampsia group(34 patients with preeclampsia). The concentrations of serum PLGF,SFLT-1,and GLYFN at the 16th to 18th weeks of gestation were measured by immunofluorescence assay. The levels of individual markers were compared between the preeclampsia group and the control group. The receiver operating characteristic(ROC) curves were used to assess the efficiency of the three markers in terms of predictive value. Results During the mid-pregnancy period,the preeclampsia group had a significantly lower concentration of serum PLGF but significantly higher concentrations of serum SFLT-1 and GLYFN compared with the control group(all P=0.000). The areas under the ROC curve(AUC) for the 95% confidence interval were 0.941(0.907-0.974),0.881(0.800-0.962),and 0.951(0.918-0.985) for PLGF,SFLT-1,and GLYFN,respectively. The AUCs for SFLT-1 combined with GLYFN and the combined detection of the three indices were 0.968 and 0.986,respectively. Conclusion There are significant differences between the control group and the preeclampsia group in the marker levels of serum PLGF,SFLT-1,and GLYFN,which has some value in predicting the onset of preeclampsia. The predictive value of SFLT-1 combined with PLGF,SFLT-1 combined with GLYFN,and the combination of the three markers are greater than that of any single index.

关键词

子痫前期 / 胎盘生长因子 / 可溶性fms样酪氨酸激酶-1 / 糖基化纤连蛋白

Key words

preeclampsia / placental growth factor / soluble fms-like tyrosine kinase-1 / glycosylated fibronectin

中图分类号

R71

引用本文

导出引用
杨岚 , 肖建平 , 石皓 , . 胎盘生长因子、可溶性fms样酪氨酸激酶-1及糖基化纤连蛋白在子痫前期预测中的应用价值. 重庆医科大学学报. 2024, 49(01): 50-54 https://doi.org/10.13406/j.cnki.cyxb.003412
Yang Lan, Xiao Jianping, Shi Hao, et al. Application value of placental growth factor,soluble fms-like tyrosine kinase-1,and glycosylated fibronectin in the prediction of preeclampsia[J]. Journal of Chongqing Medical University. 2024, 49(01): 50-54 https://doi.org/10.13406/j.cnki.cyxb.003412

参考文献

1
曹泽毅. 中华妇产科学[M]. 2版. 北京:人民卫生出版社,2004:39.
Cao ZY. Chinese obstetrics and gynecology[M]. 2nd ed. Beijing:People’s Medical Publishing House,2004:39.
2
Duhig K Vandermolen B Shennan A. Recent advances in the diagnosis and management of pre-eclampsia[J]. F1000Res20187:242.
3
Cirillo PM Cohn BA. Pregnancy complications and cardiovascular disease death:50-year follow-up of the Child Health and Development Studies pregnancy cohort[J]. Circulation2015132(13):1234-1242.
4
Ives CW Sinkey R Rajapreyar I,et al. Preeclampsia-patho-physiology and clinical presentations:JACC state-of-the-art review[J]. J Am Coll Cardiol202076(14):1690-1702.
5
Gestational hypertension and preeclampsia:ACOG practice bulletin,number 222[J]. Obstet Gynecol2020135(6):e237-e260.
6
Waugh J Bell SC Kilby MD,et al. Urine protein estimation in hypertensive pregnancy:which thresholds and laboratory assay best predict clinical outcome?[J]. Hypertens Pregnancy200524(3):291-302.
7
孙文静,胡孟彩,崔世红,等. 妊娠相关血浆蛋白A、胎盘生长因子联合胆红素对子痫前期的预测价值[J]. 中外医学研究202119(4):74-77.
Sun WJ Hu MC Cui SH,et al. Predictive value of PAPP-A,PLGF and bilirubin in preeclampsia[J]. Chin Foreign Med Res202119(4):74-77.
8
Zeisler H Llurba E Chantraine F,et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia[J]. N Engl J Med2016374(1):13-22.
9
Hypertension in pregnancy. report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy[J]. Obstet Gynecol2013122(5):1122-1131.
10
Phipps E Prasanna D Brima W,et al. Preeclampsia:updates in pathogenesis,definitions,and guidelines[J]. Clin J Am Soc Nephrol201611(6):1102-1113.
11
Brown MA Magee LA Kenny LC,et al. The hypertensive disorders of pregnancy:ISSHP classification,diagnosis & management recommendations for international practice[J]. Pregnancy Hypertens201813:291-310.
12
Liu N Guo YN Gong LK,et al. Advances in biomarker development and potential application for preeclampsia based on pathogenesis[J]. Eur J Obstet Gynecol Reprod Biol X20219:100119.
13
Kuupiel D Bawontuo V Mashamba-Thompson TP. Improving the accessibility and efficiency of point-of-care diagnostics services in low- and middle-income countries:lean and agile supply chain management[J]. Diagnostics20177(4):58.
14
Wang P Kricka LJ. Current and emerging trends in point-of-care technology and strategies for clinical validation and implementation[J]. Clin Chem201864(10):1439-1452.
15
Zhao MT Zhu ZQ Liu CD,et al. Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia:a systematic review and meta-analysis[J]. Arch Gynecol Obstet2017295(5):1079-1087.
16
常梓殷,沈 琦,杨小风,等. 胎盘生长因子水平联合唐氏筛查结果预测子痫前期的价值[J]. 医药论坛杂志202142(23):7-10,17.
Chang ZY Shen Q Yang XF,et al. Value of concentration of PLGF combined with Down’s screening results in predicting preeclampsia[J]. J Med Forum202142(23):7-10,17.
17
邱德稳,钟 师,曾辛. 血脂指标与胎盘生长因子联合检测对子痫前期的诊断价值[J]. 检验医学与临床202118(6):781-784.
Qiu DW Zhong S Zeng X. The diagnostic value of combined detection of blood lipid indexes and placental growth factor for preeclampsia[J]. Lab Med Clin202118(6):781-784.
18
Fillion A Guerby P Lachance C,et al. Placental growth factor and soluble,fms-like tyrosine kinase-1 in preeclampsia:a case-cohort(PEARL) study[J]. J D'obstetrique Gynecol Du Can202042(10):1235-1242.
19
马锦琪,李 鹰,黄建荣,等. 胎盘生长因子荧光免疫层析法检测的临床性能评估[J]. 南京医科大学学报(自然科学版)202141(1):54-58,64.
Ma JQ Li Y Huang JR,et al. Performance evaluation of placental growth factor by fluorescence immunochromatography[J]. J Nanjing Med Univ Nat Sci202141(1):54-58,64.
20
Nagalla SR Janaki V Vijayalakshmi AR,et al. Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting:a prospective Southeast Asian population study[J]. BJOG2020127(13):1687-1694.
21
DiPrisco B Kumar A Kalra B,et al. Glycosylated fibronectin and inhibin are lower and anti-müllerian hormone is higher in umbilical cord blood when mothers have preeclampsia[J]. Endocr Pract202026(3):318-327.

基金

无锡市科技发展医疗卫生计划资助项目(NZ2019016)
无锡市“双百”中青年医疗卫生人才资助项目(HB2020074)
无锡市医学创新团队资助项目(CXTD2021016)

评论

PDF(685 KB)

Accesses

Citation

Detail

段落导航
相关文章

/